Abstract
Novel 2-amino(substituted pyrimidin-2-yl)benzimidazole and 2-amino-3,4-dihydro[1,3,5]triazino[1,2-a]benzimidazole hybrids were synthesized and evaluated for their in vitro antitumor activity at National Cancer Institute (NCI), against 60 human cell lines for primary anticancer screening. Among the tested compounds, 8 and 23 exhibited significant growth inhibition. Compound 8 was very promising anticancer; therefore, this compound passed on to further evaluation at five concentration levels (0.01–100 uM), and it showed potent activity in five-dose testing. Detailed synthesis, spectroscopic, and biological data are reported.
Acknowledgments
We are grateful to the authority of National Cancer Institute (Bethesda, Maryland, USA) for carrying out the in vitro anticancer screening.